APA

Barbier A. J., Bielefeld B., Whiteman D. A. H., Natarajan M., Pano A. & Amato D. A. (20140508). The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. : Molecular genetics and metabolism.

Chicago

Barbier A J, Bielefeld B, Whiteman D A H, Natarajan M, Pano A and Amato D A. 20140508. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. : Molecular genetics and metabolism.

Harvard

Barbier A. J., Bielefeld B., Whiteman D. A. H., Natarajan M., Pano A. and Amato D. A. (20140508). The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. : Molecular genetics and metabolism.

MLA

Barbier A J, Bielefeld B, Whiteman D A H, Natarajan M, Pano A and Amato D A. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. : Molecular genetics and metabolism. 20140508.